²é¿´: 7449  |  »Ø¸´: 18
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

zasxcdcd

½ð³æ (СÓÐÃûÆø)

[½»Á÷] ÇëÎÊÒ»ÏÂͶ¸å±»Crosscheck²é³öÀ´31%£¬±à¼­ÒªÇó»ØÓ¦£¬¸ÃÈçºÎÓ¦¶Ô ÒÑÓÐ12È˲ÎÓë

֮ǰͶ¸å1¸öÔ¸ø»Ø´óÐÞ£¬Ð޸ĺ󷵻ر༭£¬ÓÖÁ½¸öÐÇÆÚ·¢À´ÐÅСÐÞ£¬µ«ÊÇÀïÃæ³ýÁËÉó¸åÈ˵ÄÒâ¼ûÖ®Í⻹дÁËÕâÑùÒ»¶Î»°£º
In addition, as you are aware, ACS is screening all manuscripts against the CrossCheck Database. As a result of this process we have received a similarity index greater than 30% for your manuscript. The iThenticate summary report obtained for your manuscript is attached. In particular, there are several statements in your manuscript that are verbatim text from: XXX., et al. Advanced Drug Delivery Reviews 20XX, XX, XX

Ö®ºó²é¿´Á˸½¼þÀïÃæÐ´ÁËSimilarity Index £º31%
¿´ÁËһϣ¬±à¼­Ìáµ½µÄÄÇÆªÓÐ5%£¬¶¼ÊÇÔÚintroductionµÄ±³¾°½éÉÜÀïÃæ
ʣϵÄÈô¸É¶¼ÊÇ<1%µÄ Óкö඼ÊÇʲôÊÔ¼ÁÃû³Æ»òÕßÒÇÆ÷Ãû³ÆµÄ°¡£¬±ÈÈç"1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Sigma,  USA)  and N-Hydroxysuccinimide (NHS, Sigma,  USA)"ÓÖ»òÕßÊÇ"Samples were measured by dynamic light scattering with a Zetasizer Nano ZS90 (Malvern Instruments Ltd, Malvern, UK)"£¬
»¹ÓÐһЩ·½·¨Ñ§µÄ²¿·Ö£¬Ò»Ð©ÖîÈçHPLCµÄÁ÷ËÙÒÔ¼°¼ì²â²¨³¤¡£¡£¡£ºÜÎÞÓï
ÁíÍ⻹ÓÐһЩ¾ÍÈÃÎÒ¿ÞЦ²»µÃÁË£¬°üÀ¨" Statistical analysis was performed using Student's T-test or  one  -way analysis of variance (ANOVA) test"ÕâÑùµÄ¾ä×Ó£¬ÒÔ¼°ÔÚͼ±íÏ·½µÄ¡°Data were  expressed  as Mean  ¡À S.D. , *P<0.05 vs CON group, #P<0.05 vs XXX  group¡±£¬ÕâÑùµÄÒ²»á±»ÈÏÎªÖØ¸´³­Ï®²¿·Ö¡£
ÇëÎʸ÷λ³æÓÑÕâÖÖÇé¿öÓ¦¸ÃÔõÑùÐÞ¸ÄÄØ£¬ÎÒÊÇÖ÷ÒªÐÞ¸ÄÒ»ÏÂÇ°ÃæµÄ5%µÄ²¿·Ö£¬»¹ÊÇ˵ËùÓвé³öÀ´µÄ²¿·Ö¶¼ÒªÐÞ¸ÄÄØ£¬È»ºó»Ø¸ø±à¼­ÓÖÒªÔõÑù˵Ã÷ÄØ£¬»á²»»áÖ±½Ó¾Í±»±ÐµôÁË ¡£¡£¡£Ð»Ð»¸÷λ³æÓÑÁË£¡
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

weiwei1983

ľ³æ (ÖøÃûдÊÖ)

Ìú¸Ëľ³æ

ѧϰѧϰ£¡

[ ·¢×ÔСľ³æ¿Í»§¶Ë ]
¼ÓÓÍ£¡¼ÓÓÍ£¡¼ÓÓÍС±¿Å££¡¼ÓÓÍСľ³æ£¡
13Â¥2014-12-08 19:52:00
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 19 ¸ö»Ø´ð

×Ô˽µÄè1988

ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
book2005593: ½ð±Ò+1, ¹ÄÀø²ÎÓë½»Á÷~ 2014-11-17 13:52:18
Ö±½Ó˵Ã÷ÕæÊµÇé¿ö£¬²»ÒªÒþÂ÷£¬Ö÷ÒªÊÇÄÄЩµØ·½µÄÖØ¸´Ô­Òò£¬Ò»Ð©ÄÜÐ޸ĵĵط½ÐÞ¸ÄÒ»ÏÂ
2Â¥2014-11-17 10:12:31
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

zasxcdcd

½ð³æ (СÓÐÃûÆø)

ÒýÓûØÌû:
2Â¥: Originally posted by ×Ô˽µÄè1988 at 2014-11-17 10:12:31
Ö±½Ó˵Ã÷ÕæÊµÇé¿ö£¬²»ÒªÒþÂ÷£¬Ö÷ÒªÊÇÄÄЩµØ·½µÄÖØ¸´Ô­Òò£¬Ò»Ð©ÄÜÐ޸ĵĵط½ÐÞ¸ÄÒ»ÏÂ

ÕâÖÖÇé¿ö±»¾ÜµÄ¿ÉÄÜÓжà´ó¡£¡£¡£
3Â¥2014-11-17 11:01:26
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

klmopq

ľ³æ (СÓÐÃûÆø)

¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
book2005593: ½ð±Ò+2, ¹ÄÀø½»Á÷~ 2014-11-17 13:52:39
Сľ³æ: ½ð±Ò+2, Ìû×ÓÕæ¾«²Ê 2014-11-23 16:25:33
ÎҵĻظ´
Dear Prof¡¤¡¤¡¤¡¤¡¤,

We would like to express our sincere apologies to have so many overlapped descriptions in our manuscript, and we also really appreciate that you give us the opportunity to make explanation. We have provided the explanations in the following paragraph and revised the manuscript to avoid overlapped sentences with our previous papers. The revised parts have been highlighted in the submitted manuscript.

Firstly, we would like to emphasize that this work is novel and different from our previous work and literature reports, which has been demonstrated by the positive comments from peer-reviewers. We also believed it has significant scientific impacts to be published in JPCC. For the overlapped descriptions, our reasons are as followed.

1.        The major overlapped descriptions are in the experimental parts. ¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤
2.        Another major overlapped parts are the affiliation and acknowledgment which is the same as our previous published paper¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤. This is inevitable, because we are still working in the same university and supported by the same funding programs.
3.        The others overlapped parts are minor, and mainly on the technical languages, such as ¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤
4.        The fixed phrases of physical symbol annotations were overlapped, for example, ¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤¡¤
¸øÂú·ÖÎÒ°É£¡£¡£¡
4Â¥2014-11-17 11:15:41
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 085700×ÊÔ´Óë»·¾³308Çóµ÷¼Á +4 īīĮ 2026-03-18 4/200 2026-03-19 21:46 by wang_dand
[¿¼ÑÐ] 0856µ÷¼Á£¬ÊÇѧУ¾ÍÈ¥ +6 sllhht 2026-03-19 7/350 2026-03-19 19:50 by ÖÆ¶ÈµÄ
[¿¼ÑÐ] 288Çóµ÷¼Á +14 ÓÚº£º£º£º£ 2026-03-19 14/700 2026-03-19 19:40 by maocaozhuxi
[¿¼ÑÐ] 321Çóµ÷¼Á +8 ºÎÈó²É123 2026-03-18 10/500 2026-03-19 16:46 by ºÎÈó²É123
[¿¼²©] ¶«»ªÀí¹¤´óѧ»¯²Äרҵ26½ì˶ʿ²©Ê¿ÉêÇë +8 zlingli 2026-03-13 8/400 2026-03-19 16:32 by ÇáËɲ»ÉÙËæ
[¿¼ÑÐ] ¡¾¿¼Ñе÷¼Á¡¿»¯Ñ§×¨Òµ 281·Ö£¬Ò»Ö¾Ô¸ËÄ´¨´óѧ£¬³ÏÐÄÇóµ÷¼Á +5 ³Ô³Ô³Ô²ÅÓÐÒâÒå 2026-03-19 5/250 2026-03-19 16:18 by 30660438
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤Çóµ÷¼Á +7 Ϊѧ666 2026-03-16 7/350 2026-03-19 14:48 by ¾¡Ë´Ò¢1
[¿¼ÑÐ] 354Çóµ÷¼Á +4 Tyoumou 2026-03-18 7/350 2026-03-18 21:45 by Tyoumou
[¿¼ÑÐ] 331Çóµ÷¼Á£¨0703Óлú»¯Ñ§ +7 ZY-05 2026-03-13 8/400 2026-03-18 14:13 by 007_lilei
[¿¼ÑÐ] 265Çóµ÷¼Á +3 ÁºÁºÐ£Ð£ 2026-03-17 3/150 2026-03-18 09:12 by zhukairuo
[¿¼ÑÐ] 334Çóµ÷¼Á +3 Ö¾´æ¸ßÔ¶ÒâÔÚ»úÐ 2026-03-16 3/150 2026-03-18 08:34 by lm4875102
[¿¼ÑÐ] 308Çóµ÷¼Á +4 ÊÇLupa°¡ 2026-03-16 4/200 2026-03-17 17:12 by ruiyingmiao
[¿¼ÑÐ] ²ÄÁÏר˶326Çóµ÷¼Á +6 Ä«ìÏæ¦Ý· 2026-03-15 7/350 2026-03-17 17:10 by ruiyingmiao
[¿¼ÑÐ] 302Çóµ÷¼Á +4 С¼Öͬѧ123 2026-03-15 8/400 2026-03-17 10:33 by С¼Öͬѧ123
[¿¼ÑÐ] 283Çóµ÷¼Á +3 Ìý·ç¾ÍÊÇÓꣻ 2026-03-16 3/150 2026-03-17 07:41 by ÈÈÇéɳĮ
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤ Çóµ÷¼Á +13 enenenhui 2026-03-13 14/700 2026-03-16 15:19 by ÁËÁËÁËÁË¡£¡£
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÖÐʦ·¶071000£¬325Çóµ÷¼Á +6 RuitingC 2026-03-12 6/300 2026-03-16 14:50 by ¿Éµ­²»¿ÉÍü
[¿¼ÑÐ] ¸´ÊÔµ÷¼Á +3 ºôºô£¿~+123456 2026-03-14 3/150 2026-03-14 16:53 by WTUChen
[¿¼ÑÐ] Ò»Ö¾Ô¸¹þ¹¤´ó²ÄÁÏ324·ÖÇóµ÷¼Á +5 ãÆÐñ¶« 2026-03-14 5/250 2026-03-14 14:53 by ľ¹Ï¸à
[¿¼²©] ¸£ÖÝ´óѧÑî»ÆºÆ¿ÎÌâ×éÕÐÊÕ2026Äêרҵѧλ²©Ê¿Ñо¿Éú£¬2026.03.20½ØÖ¹ +3 Xiangyu_ou 2026-03-12 3/150 2026-03-13 09:36 by duanwu655
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û